These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 28296257

  • 1. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
    Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, Pease CT, Price EJ, Sutcliffe N, Gendi NST, Hall FC, Ruddock SP, Fernandez C, Reynolds C, Hulme CT, Davies KA, Edwards CJ, Lanyon PC, Moots RJ, Roussou E, Giles IP, Sharples LD, Bombardieri M.
    Arthritis Rheumatol; 2017 Jul; 69(7):1440-1450. PubMed ID: 28296257
    [Abstract] [Full Text] [Related]

  • 2. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Yves Hatron P, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Saliou P, Pers JO, Seror R, Saraux A.
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [Abstract] [Full Text] [Related]

  • 3. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
    Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Seror R, Pers JO, Meiners PM, Vissink A, Bootsma H, Nowak E, Saraux A.
    Rheumatology (Oxford); 2015 Sep; 54(9):1699-708. PubMed ID: 25957440
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
    Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H.
    Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, Desmoulins F, Nocturne G, Ravaud P, De Vita S.
    Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
    [Abstract] [Full Text] [Related]

  • 6. Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.
    Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, Marhadour T, Bressollette L, Gestin S, Pers JO, Nowak E, Saraux A.
    Arthritis Rheumatol; 2015 Jun; 67(6):1623-8. PubMed ID: 25708147
    [Abstract] [Full Text] [Related]

  • 7. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
    Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, Devauchelle-Pensec V, Morel J, Hayem G, Hatron P, Perdriger A, Sene D, Zarnitsky C, Batouche D, Furlan V, Benessiano J, Perrodeau E, Seror R, Mariette X.
    JAMA; 2014 Jul 16; 312(3):249-58. PubMed ID: 25027140
    [Abstract] [Full Text] [Related]

  • 8. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
    Khurshudian AV.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan 16; 95(1):38-44. PubMed ID: 12539025
    [Abstract] [Full Text] [Related]

  • 9. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.
    Brown S, Navarro Coy N, Pitzalis C, Emery P, Pavitt S, Gray J, Hulme C, Hall F, Busch R, Smith P, Dawson L, Bombardieri M, Wan-Fai N, Pease C, Price E, Sutcliffe N, Woods C, Ruddock S, Everett C, Reynolds C, Skinner E, Poveda-Gallego A, Rout J, Macleod I, Rauz S, Bowman S, TRACTISS trial team.
    BMC Musculoskelet Disord; 2014 Jan 17; 15():21. PubMed ID: 24438039
    [Abstract] [Full Text] [Related]

  • 10. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J.
    Arthritis Rheum; 2004 Apr 17; 50(4):1270-6. PubMed ID: 15077311
    [Abstract] [Full Text] [Related]

  • 11. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X, Li X, Li X, Li Z, Zhao D, Liu S, Zhang M, Zhang F, Zhu P, Chen J, Wei W, Lin B, Zhou Y, Chen J, Pang Y, Zhang L, Sun X, Yu Z, Jia Y, Wang J, Sun W, Chiu F, Pang L, Wang G.
    Clin Rheumatol; 2019 Mar 17; 38(3):657-664. PubMed ID: 30280368
    [Abstract] [Full Text] [Related]

  • 12. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S, Bootsma H.
    Ann Rheum Dis; 2014 Jul 17; 73(7):1393-6. PubMed ID: 24473674
    [Abstract] [Full Text] [Related]

  • 13. Physical fatigue characterises patient experience of primary Sjögren's syndrome.
    Arends S, Meiners PM, Moerman RV, Kroese FG, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Clin Exp Rheumatol; 2017 Jul 17; 35(2):255-261. PubMed ID: 28032845
    [Abstract] [Full Text] [Related]

  • 14. World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review.
    Gueiros LA, France K, Posey R, Mays JW, Carey B, Sollecito TP, Setterfield J, Woo SB, Culton D, Payne AS, Lodi G, Greenberg MS, De Rossi S.
    Oral Dis; 2019 Jun 17; 25 Suppl 1(Suppl 1):102-110. PubMed ID: 31140693
    [Abstract] [Full Text] [Related]

  • 15. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P.
    Ann Rheum Dis; 2008 Nov 17; 67(11):1541-4. PubMed ID: 18276741
    [Abstract] [Full Text] [Related]

  • 16. Primary Sjögren's syndrome in Moroccan patients: characteristics, fatigue and quality of life.
    Ibn Yacoub Y, Rostom S, Laatiris A, Hajjaj-Hassouni N.
    Rheumatol Int; 2012 Sep 17; 32(9):2637-43. PubMed ID: 21786120
    [Abstract] [Full Text] [Related]

  • 17. Meta-Analysis of Treatment for Primary Sjögren's Syndrome.
    Chu LL, Cui K, Pope JE.
    Arthritis Care Res (Hoboken); 2020 Jul 17; 72(7):1011-1021. PubMed ID: 31058469
    [Abstract] [Full Text] [Related]

  • 18. Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis.
    Souza FB, Porfírio GJ, Andriolo BN, Albuquerque JV, Trevisani VF.
    PLoS One; 2016 Jul 17; 11(3):e0150749. PubMed ID: 26998607
    [Abstract] [Full Text] [Related]

  • 19. Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
    Posada J, Valadkhan S, Burge D, Davies K, Tarn J, Casement J, Jobling K, Gallagher P, Wilson D, Barone F, Fisher BA, Ng WF.
    Arthritis Rheumatol; 2021 Jan 17; 73(1):143-150. PubMed ID: 32798283
    [Abstract] [Full Text] [Related]

  • 20. Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome.
    Theander E, Horrobin DF, Jacobsson LT, Manthorpe R.
    Scand J Rheumatol; 2002 Jan 17; 31(2):72-9. PubMed ID: 12109650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.